Absci (ABSI) Cash from Financing Activities (2020 - 2026)
Absci (ABSI) reported Cash from Financing Activities of $7.6 million for Q1 2026, down 82.34% on a YoY basis from $42.8 million in Q1 2025, and up 96.67% sequentially from $3.8 million in Q4 2025.
Absci (ABSI) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Absci (ABSI) has 7 years of Cash from Financing Activities data on file, last reported at $7.6 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 82.34% year-over-year to $7.6 million; the trailing twelve-month figure through Mar 2026 stood at $70.7 million (up 60.21% YoY), and the FY2025 full-year result was $105.9 million, up 28.38% from the prior year.
- Cash from Financing Activities improved to $7.6 million in Q1 2026, from $3.8 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $81.2 million in Q1 2024 to a low of -$1.2 million in Q4 2023.
- A 5-year average of $11.6 million and a median of $490000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 12209.59% in 2025, while the deepest fall reached 649.25% in 2025.
- Tracing ABSI's Cash from Financing Activities over 5 years: stood at $1.4 million in 2022, then tumbled by 188.66% to -$1.2 million in 2023, then soared by 179.84% to $986000.0 in 2024, then soared by 289.66% to $3.8 million in 2025, then jumped by 96.67% to $7.6 million in 2026.
- Business Quant data shows ABSI's Cash from Financing Activities at $7.6 million in Q1 2026, $3.8 million in Q4 2025, and $60.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Absci | 1.23 Bn | 1.11 Bn | - | 7.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.56 Mn |
| Mar 31, 2026 | 7.56 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 60.32 Mn |
| Sep 30, 2025 | 60.32 Mn |
| Jun 30, 2025 | -1.00 Mn |
| Jun 30, 2025 | -1.00 Mn |
| Mar 31, 2025 | 42.79 Mn |
| Mar 31, 2025 | 42.79 Mn |
| Dec 31, 2024 | 986,000.00 |
| Dec 31, 2024 | 986,000.00 |
| Sep 30, 2024 | 490,000.00 |
| Sep 30, 2024 | 490,000.00 |
| Jun 30, 2024 | -134,000.00 |
| Jun 30, 2024 | -134,000.00 |
| Mar 31, 2024 | 81.18 Mn |
| Mar 31, 2024 | 81.18 Mn |
| Dec 31, 2023 | -1.24 Mn |
| Dec 31, 2023 | -1.24 Mn |